7 January 2020

Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, has announced Syncona Ltd (Syncona) has made an $80.0 million (£61.1 million) commitment in a Series C financing and has funded the first tranche of this commitment, amounting to $40.0 million (£30.6 million)[2]. This financing augments the previous £88.4 million Series B investment and the £34.8 million Series A investment previously made into Freeline by the founding investors, led by Syncona.

Visit the Freeline website to view the full article.